CC BY 4.0 · Rev Bras Ortop (Sao Paulo)
DOI: 10.1055/s-0044-1786200
Artigo Original

Three-dimensional Evaluation of Gait: Kinetics, Kinematics, and Electromyographic in Patients with Mucopolysacharidosis Types IV and VI

Article in several languages: português | English
1   Universidade Federal de Pernambuco, Recife, PE, Brasil
,
1   Universidade Federal de Pernambuco, Recife, PE, Brasil
,
1   Universidade Federal de Pernambuco, Recife, PE, Brasil
› Author Affiliations
Financial Support There was no financial support from public, commercial, or not-for-profit sources.

Abstract

Objective This study evaluated and determined, through instrumented three-dimensional (3D) gait analysis, the kinetic, kinematic, and electromyographic profile of patients with mucopolysaccharidosis (MPS) IV and VI.

Methods This crossectional study included 11 patients treated at a rare diseases reference service and evaluated in a movement analysis laboratory. We collected clinical, physical examination, and kinetic, kinematic, and electromyographic data using a 3D movement system, from June 2020 to January 2021.

Results There were 5 (45.5%) female patients, and 6 (54.5%) males. Furthermore, 9 (81.8%) subjects had MPS VI, and 2 (18.2%) had MPS IV. Their average age was 14.6 years. The average speed was 0.68 m/s (±0.21), and the stride length was 0.66 (±0.15). The most altered static angles were the hips' abduction-adduction, knees' range of movement, and foot's progression angle. Most cases presented a gait pattern of hip flexion-adduction and knee flexion. The gait profile scale (GPS) was 14.58 (±6.72) on the right side and 11.71 (±3.39) on the left. The gait deviation index (GDI) was 73.23 (±14.50) on the right side and 80.45 (±17.05) on the left. Muscle activity approximately followed the current model.

Conclusion The patients showed a decreased average speed and stride length. Most cases presented a gait pattern of hip flexion-adduction and knee flexion. Both GPS and GDI showed a significant deviation from normality.

Study developed at the Universidade Federal de Pernambuco, Hospital Maria Lucinda, and Movement Analysis Laboratory, Instituto Rolim, Recife, PE, Brazil.




Publication History

Received: 19 April 2023

Accepted: 21 July 2023

Article published online:
22 July 2024

© 2024. The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution 4.0 International License, permitting copying and reproduction so long as the original work is given appropriate credit (https://creativecommons.org/licenses/by/4.0/)

Thieme Revinter Publicações Ltda.
Rua do Matoso 170, Rio de Janeiro, RJ, CEP 20270-135, Brazil

 
  • Referências

  • 1 Gaffke L, Pierzynowska K, Podlacha M, Brokowska J, Węgrzyn G. Changes in cellular processes occurring in mucopolysaccharidoses as underestimated pathomechanisms of these diseases. Cell Biol Int 2021; 45 (03) 498-506
  • 2 Herring JA, Tachdjian MO. Texas Scottish Rite Hospital for Children. 5th ed.. Philadelphia: Saunders; 2013: 455
  • 3 Çelik B, Tomatsu SC, Tomatsu S, Khan SA. Epidemiology of Mucopolysaccharidoses Update. Diagnostics (Basel) 2021; 11 (02) 273
  • 4 Federhen A, Pasqualim G, de Freitas TF. et al. Estimated birth prevalence of mucopolysaccharidoses in Brazil. Am J Med Genet A 2020; 182 (03) 469-483
  • 5 Pinto LL, Schwartz IV, Puga AC, Vieira TA, Munoz MV, Giugliani R. Prospective study of 11 Brazilian patients with mucopolysaccharidosis II. J Pediatr (Rio J) 2006; 82 (04) 273-278
  • 6 Del Longo A, Piozzi E, Schweizer F. Ocular features in mucopolysaccharidosis: diagnosis and treatment. Ital J Pediatr 2018; 44 (Suppl. 02) 125
  • 7 Barone R, Pellico A, Pittalà A, Gasperini S. Neurobehavioral phenotypes of neuronopathic mucopolysaccharidoses. Ital J Pediatr 2018; 44 (Suppl. 02) 121
  • 8 Kubaski F, de Oliveira Poswar F, Michelin-Tirelli K. et al. Diagnosis of Mucopolysaccharidoses. Diagnostics (Basel) 2020; 10 (03) 172
  • 9 Cardoso-Santos A, Azevedo AC, Fagondes S, Burin MG, Giugliani R, Schwartz IV. Mucopolysaccharidosis type VI (Maroteaux-Lamy syndrome): assessment of joint mobility and grip and pinch strength. J Pediatr (Rio J) 2008; 84 (02) 130-135
  • 10 Davis RB, Ounpuu S, Tyburski D, Gage JR. A gait analysis data collection and reduction technique. Hum Mov Sci 1991; 10 (05) 575-587
  • 11 Souza MA, Cezarani A, Lizzi EADS. et al. The use of the gait profile score and gait variable score in individuals with Duchenne Muscular Dystrophy. J Biomech 2020; 98: 109485
  • 12 Schwartz IV, Ribeiro MG, Mota JG. et al. A clinical study of 77 patients with mucopolysaccharidosis type II. Acta Paediatr 2007; 96 (455) 63-70
  • 13 Sutherland DH. The evolution of clinical gait analysis part l: kinesiological EMG. Gait Posture 2001; 14 (01) 61-70
  • 14 Dhawale AA, Church C, Henley J. et al. Gait pattern and lower extremity alignment in children with Morquio syndrome. J Pediatr Orthop B 2013; 22 (01) 59-62
  • 15 Akyol MU, Alden TD, Amartino H. et al; MPS Consensus Programme Steering Committee, MPS Consensus Programme Co-Chairs. Recommendations for the management of MPS VI: systematic evidence- and consensus-based guidance. Orphanet J Rare Dis 2019; 14 (01) 118
  • 16 Matos MA, Prado A, Schenkel G, Barreto R, Acosta AX. Energy expenditure during gait in patients with mucopolysaccharidosis. Acta Ortop Bras 2013; 21 (02) 116-119
  • 17 Schmid S, Schweizer K, Romkes J, Lorenzetti S, Brunner R. Secondary gait deviations in patients with and without neurological involvement: a systematic review. Gait Posture 2013; 37 (04) 480-493
  • 18 Patterson KK, Nadkarni NK, Black SE, McIlroy WE. Gait symmetry and velocity differ in their relationship to age. Gait Posture 2012; 35 (04) 590-594
  • 19 Baker R, Esquenazi A, Benedetti MG, Desloovere K. Gait analysis: clinical facts. Eur J Phys Rehabil Med 2016; 52 (04) 560-574
  • 20 Lin HY, Lee CL, Lo YT. et al. The relationships between urinary glycosaminoglycan levels and phenotypes of mucopolysaccharidoses. Mol Genet Genomic Med 2018; 6 (06) 982-992
  • 21 Salazar-Torres JJ, Church C, Shields T. et al. Evaluation of Gait Pattern and Lower Extremity Kinematics of Children with Morquio Syndrome (MPS IV). Diagnostics (Basel) 2021; 11 (08) 1350
  • 22 Kimoto M, Okada K, Sakamoto H, Kondou T, Kawanobe U. Relationship between walking efficiency and muscular strength of the lower limbs in children with cerebral palsy. J Phys Ther Sci 2019; 31 (03) 232-235
  • 23 Hahn ME, Chou LS. Can motion of individual body segments identify dynamic instability in the elderly?. Clin Biomech (Bristol, Avon) 2003; 18 (08) 737-744
  • 24 Ellis RG, Howard KC, Kram R. The metabolic and mechanical costs of step time asymmetry in walking. Proc Biol Sci 2013; 280 (1756) 20122784
  • 25 Neufeld EF, Muenzer J. The mucoplysaccharidoses. In: Scriver CR. et al. The metabolic and molecular bases of inherited disease. 8 th ed.. New York: McGraw-Hill; 2001: 3421-3452
  • 26 Massaad A, Assi A, Skalli W, Ghanem I. Repeatability and validation of gait deviation index in children: typically developing and cerebral palsy. Gait Posture 2014; 39 (01) 354-358
  • 27 Agostini V, Nascimbeni A, Gaffuri A, Imazio P, Benedetti MG, Knaflitz M. Normative EMG activation patterns of school-age children during gait. Gait Posture 2010; 32 (03) 285-289
  • 28 Granata KP, Padua DA, Abel MF. Repeatability of surface EMG during gait in children. Gait Posture 2005; 22 (04) 346-350
  • 29 Fleming AM, Ribeiro CT, Horovitz DG, Ribeiro LC, Correa AP. Description of functioning in children and adolescents with mucopolysaccharidosis-case series. J Inborn Errors Metab Screen 2020; 8: e20190010